Gene Therapy Stocks: 5 Catalysts Worth $20B by Q1 2027

Gene therapy had a brutal 2023 to 2024. Funding collapsed. Clinical trials stalled. The FDA approved a handful of treatments, but the stocks got crushed. The narrative was simple: the science works, but the business model does not. One-time curative therapies priced at $2 million per patient do not generate the recurring revenue that investors want.

That narrative is about to be tested. Five catalysts in the second half of 2026 could prove that gene therapy is a viable sector, not just a science experiment. Or they could confirm that the business model is broken. Here is the setup, the catalysts, and where the value actually sits.

The Sector Setup

Gene therapy uses viral vectors, primarily adeno-associated virus (AAV), to deliver functional copies of defective genes into cells. The goal is a one-time treatment that fixes the underlying cause of a genetic disease. The science has been validated by approved products: Novartis’s Zolgensma, Bluebird’s Skysona and Zynteglo, and Vertex’s Casgevy. But the commercial trajectory has been uneven. Zolgensma peaked at $1.4 billion in 2023 and is declining. Zynteglo was pulled from the European market over pricing disputes. Casgevy is scaling slowly, as we covered in our Casgevy post-approval analysis. The sector had a funding rebound in late 2025 into 2026 driven by improved AAV manufacturing, regulatory clarity on accelerated approval pathways, and the priority review voucher program that lets rare disease sponsors sell expedited review slots for $100 million or more.

The contrarian thesis: everyone hates this sector. That is why the valuations are cheap. Ultragenyx (RARE) at $2.65 billion market cap, uniQure (QURE) at $2.68 billion, REGENXBIO (RGNX) at $623 million. These are companies with late-stage gene therapy pipelines trading at pre-clinical biotech multiples. If the catalysts hit, the re-rating is 3x to 5x. If they miss, the downside is 50 percent or more.

Catalyst 1: Ultragenyx UX111 BLA, September 19 PDUFA

UX111 (rebisufligene etisparvovec) is an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), a fatal neurodegenerative lysosomal storage disorder with no approved treatment. The disease affects 3,000 to 5,000 patients in commercially accessible geographies with a median life expectancy of 15 years.

The BLA resubmission was accepted by the FDA with a PDUFA date of September 19, 2026, under the accelerated approval pathway. This is a resubmission after a Complete Response Letter on the original filing, which Ultragenyx addressed with updated long-term data.

The clinical data comes from the Transpher A study, a Phase 1/2/3 trial with up to 8.5 years of follow-up. In the 17-patient modified intent-to-treat group (children under two years old or with earlier-stage disease), the Bayley-III cognitive raw score showed a 23.2-point treatment effect versus natural history (p<0.0001). Receptive communication improved 8.1 points (p=0.0076), expressive communication 11.1 points (p=0.0008), and fine motor 9.0 points (p=0.0026). Cerebrospinal fluid heparan sulfate, the key biomarker, decreased a median of 63.98 percent (p<0.001), with 81.5 percent of patients achieving a 50 percent or greater reduction.

This is the same drug we analyzed in our UX111 Sanfilippo PDUFA analysis. The key risk: this is a single-arm trial with no randomized comparator, using a propensity score-matched external control. The FDA accepted it under accelerated approval, which means confirmatory evidence is required. The prior CRL suggests the FDA had questions about the data package. RARE closed at $26.90 on July 24 with a market cap of $2.65 billion. A September 19 approval could move the stock 30 to 50 percent on the day. A CRL cuts it in half.

Catalyst 2: uniQure AMT-130 BLA Submission, Q3 2026

AMT-130 is an AAV5 gene therapy for Huntington’s disease, a fatal autosomal dominant neurodegenerative disorder affecting approximately 75,000 people in the US, EU, and UK. There are no approved therapies that delay onset or slow disease progression.

The FDA agreed in June 2026 that Phase 1/2 data can serve as the basis for an accelerated approval BLA, a reversal from its earlier position. uniQure plans to submit the BLA in the third quarter of 2026. The data comes from a registrational Phase 1/2 study of 29 patients (17 high dose, 12 low dose) compared to a propensity score-matched external control from the Enroll-HD natural history dataset.

At 36 months, high-dose AMT-130 demonstrated a statistically significant slowing of disease progression on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) versus the external control. The key secondary endpoint, Total Functional Capacity (TFC), also showed statistically significant slowing. Cerebrospinal fluid neurofilament light chain, a neurodegeneration biomarker, was below baseline at 36 months.

The risk: this is Phase 1/2 data with 29 patients compared to an external control, not a randomized Phase 3. The FDA agreed to accept it for accelerated approval, but the confirmatory trial design is still under discussion. QURE closed at $38.97 on July 24 with a market cap of $2.68 billion. The BLA submission is a milestone but not an approval. The stock moves on the submission and then again on the FDA decision, likely in mid-2027.

Catalyst 3: REGENXBIO Sura-Vec Registrational Data, Q4 2026

Surabgene lomparvovec (sura-vec) is an AAV8 gene therapy for wet age-related macular degeneration, developed in partnership with AbbVie. Wet AMD affects up to 2 million people in the US, Europe, and Japan. Current standard of care requires lifelong intravitreal anti-VEGF injections, often every 4 to 8 weeks. A one-time gene therapy that eliminates or reduces injection burden would be a fundamental shift in the treatment model.

REGENXBIO expects topline data from two registrational trials, ATMOSPHERE and ASCENT, in Q4 2026. Together, these trials enrolled over 1,200 patients across more than 200 sites. Five-year follow-up data presented at the ASRS meeting in July 2026 showed stable to improved visual acuity in patients who required frequent anti-VEGF injections prior to treatment. The safety profile showed no drug-related intraocular inflammation with short-course prophylactic topical steroids.

The comp question: Regeneron’s Eylea generated $5.9 billion in 2024 revenue from wet AMD and diabetic retinopathy. If sura-vec captures even 10 percent of that market, that is $590 million in annual revenue. RGNX closed at $9.73 on July 24 with a market cap of $623 million. A successful registrational readout in Q4 could justify a 3x to 5x re-rating based on the wet AMD opportunity alone. But the risk is real: gene therapy for a common eye disease is unproven, and AbbVie is the commercialization partner. RGNX receives milestones and royalties, not full economics. A failed registrational trial at $623 million market cap is a 60 to 70 percent drawdown.

Catalyst 4: Avidity Delpacibart BLA Submission, H2 2026

Avidity Biosciences (RNA) is developing delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD), a rare muscle disease with no approved treatments. FSHD affects approximately 16,000 to 38,000 patients in the US. The disease causes progressive skeletal muscle weakness, leading to loss of facial expression, arm mobility, and speech.

Del-brax uses Avidity’s proprietary antibody-siRNA conjugate (AOC) platform, which combines a monoclonal antibody targeting muscle tissue with a siRNA payload that silences the DUX4 gene responsible for FSHD. In the Phase 1/2 FORTITUDE trial, del-brax at 2 mg/kg showed greater than 50 percent reduction in DUX4-regulated genes at four months, with 25 percent or greater reductions in circulating biomarkers and creatine kinase. Avidity aligned with the FDA on accelerated and full approval pathways and plans to submit a BLA in the second half of 2026 using biomarker cohort data.

RNA closed at $11.49 on July 24 with a market cap of $196.5 million. A BLA submission for accelerated approval in FSHD with no approved competitors could move the stock substantially. But $196 million reflects the market’s skepticism about the AOC platform and the small initial dataset. The FORTITUDE biomarker cohort has 12 patients. Twelve patients is not a Phase 3. The FDA accepted the accelerated approval pathway, but the confirmatory trial requirement remains.

Catalyst 5: Sarepta DMD Franchise Continuation

Sarepta Therapeutics (SRPT) is the incumbent in Duchenne muscular dystrophy gene therapy. Elevidys (delandistrogene moxeparvovec) was approved in June 2023 and generated approximately $820 million in 2024 revenue. But the DMD pipeline is crowded, as we have covered in our Dyne rostudirsen BLA analysis and Capricor deramiocel AdCom coverage. Sarepta faces competition from Dyne’s rostudirsen (BLA under FDA review) and Capricor’s deramiocel (AdCom July 29).

SRPT closed at $15.68 on July 24 with a market cap of $1.66 billion, down from 2023 highs above $150. The stock has been crushed by safety concerns, label restrictions, and the competitive threat from Dyne. At $1.66 billion, Sarepta is being priced as if Elevidys revenue is at risk. If Dyne’s rostudirsen is approved and captures market share, Sarepta’s franchise erodes. But Sarepta has first-mover advantage and an established commercial infrastructure. The comp: Dyne (DYN) at $3.95 billion with zero revenue and one BLA under review is worth 2.4x Sarepta at $1.66 billion with $820 million in revenue. That is the market saying Dyne’s drug is better. If the market is wrong, Sarepta is the contrarian buy.

Risks

The risks are specific and structural. First, AAV manufacturing is the bottleneck. Vector supply constraints have delayed multiple gene therapy programs, and scaling AAV production to commercial volumes remains technically difficult. Second, immunogenicity limits the patient population. Pre-existing antibodies to AAV vectors disqualify a significant percentage of patients, capping the addressable market. Third, the $2 million pricing model is under pressure from payers. Fourth, all five catalysts depend on the FDA’s accelerated approval pathway. If the FDA tightens standards, the regulatory risk for single-arm trials increases. For context, see our guide to accelerated approval and what a Complete Response Letter means.

The Verdict

Gene therapy is a contrarian sector. The valuations reflect failure. RARE at $2.65 billion, QURE at $2.68 billion, RGNX at $623 million, RNA at $196.5 million, SRPT at $1.66 billion. None of these prices assumes success on the upcoming catalysts.

My ranking of the five catalysts by risk-reward:

RARE (UX111 September 19) is the most likely approval. The data is strong, the biomarker is validated, and the FDA already acknowledged the neurodevelopmental data. At $2.65 billion market cap with a first-in-class gene therapy for a fatal pediatric disease, the stock is cheap if approved.

RGNX (sura-vec Q4 2026) is the highest-reward play. Wet AMD is a $5.9 billion market. A one-time gene therapy that works would re-rate the stock from $623 million to several billion. But it is also the highest risk: Phase 3 data in 1,200 patients is binary, and gene therapy for a common disease is unproven.

QURE (AMT-130 BLA submission Q3 2026) is the longest timeline. The BLA submission is a milestone, but the FDA decision is likely mid-2027. A Huntington’s disease-modifying therapy would be historic, but the data is Phase 1/2 with 29 patients.

SRPT is the contrarian value play. At $1.66 billion with $820 million in Elevidys revenue, the stock is priced for franchise erosion. If Dyne’s rostudirsen is approved and does not capture share as aggressively as the market fears, Sarepta re-rates. But this is a bet against the consensus, and consensus has been right about Sarepta for two years.

RNA is the lottery ticket. $196.5 million market cap for a novel modality in FSHD with no approved competitors. The BLA submission in H2 2026 is the catalyst. Twelve patients is a small dataset, but the FDA accepted the accelerated approval pathway.

If I am buying gene therapy exposure, I want RARE for the September 19 PDUFA and RGNX for the Q4 2026 Phase 3 data. Those are the two catalysts with the clearest binary outcomes and the most asymmetric risk-reward. The other three are holds or watches.